Versant Capital Management Inc Purchases 1,142 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Versant Capital Management Inc boosted its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 174.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,795 shares of the medical research company’s stock after purchasing an additional 1,142 shares during the period. Versant Capital Management Inc’s holdings in NeoGenomics were worth $30,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Loomis Sayles & Co. L P bought a new stake in NeoGenomics during the 3rd quarter worth about $17,807,000. Segall Bryant & Hamill LLC grew its stake in shares of NeoGenomics by 67.0% during the third quarter. Segall Bryant & Hamill LLC now owns 1,893,407 shares of the medical research company’s stock valued at $27,928,000 after purchasing an additional 759,524 shares during the last quarter. First Light Asset Management LLC grew its stake in shares of NeoGenomics by 14.5% during the second quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock valued at $52,464,000 after purchasing an additional 480,396 shares during the last quarter. Bellevue Group AG increased its holdings in shares of NeoGenomics by 34.2% in the third quarter. Bellevue Group AG now owns 1,612,612 shares of the medical research company’s stock valued at $23,786,000 after purchasing an additional 410,516 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in NeoGenomics by 7.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company’s stock worth $46,108,000 after purchasing an additional 217,687 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at NeoGenomics

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of NeoGenomics stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $15.36, for a total transaction of $79,488.00. Following the completion of the sale, the general counsel now directly owns 37,129 shares of the company’s stock, valued at approximately $570,301.44. This trade represents a 12.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NEO. Jefferies Financial Group initiated coverage on NeoGenomics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $22.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a report on Wednesday, November 6th. Bank of America increased their target price on NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Finally, Benchmark restated a “buy” rating and issued a $18.00 price target on shares of NeoGenomics in a report on Tuesday, September 24th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, NeoGenomics presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.30.

NeoGenomics Stock Performance

NASDAQ NEO opened at $18.36 on Wednesday. The firm has a market capitalization of $2.36 billion, a P/E ratio of -30.10 and a beta of 1.24. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. The firm’s fifty day moving average price is $16.51 and its two-hundred day moving average price is $15.55. NeoGenomics, Inc. has a 1 year low of $12.77 and a 1 year high of $19.00.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.04. The business had revenue of $167.80 million during the quarter, compared to the consensus estimate of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. NeoGenomics’s revenue was up 10.5% on a year-over-year basis. During the same period last year, the business posted ($0.06) EPS. As a group, research analysts anticipate that NeoGenomics, Inc. will post -0.16 EPS for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.